19.12.2012 - Poxel has successfully closed a Series B financing round. A big share of the €13m will go into the research of glimins, a new anti-diabetics class.
This pill tastes like sugar. Investors of French Poxel SA believe in the biotech’s oral anti-diabetic drug and invest another €13m in a Series B round. Poxel from Lyon announced the news on 18 December. The financing, led by Edmond de Rothschild Investment Partners (EdRIP), included all existing investors such as the InnoBio fund managed by CDC Enterprises within FSI France Investment programme and Omnes Capital (formerly Crédit Agricole Private Equity). According to the press release, a significant part of the funds will be used to confirm efficacy data of the company's lead programme, Imeglimin. The drug is the first in a new Tetrahydrotriazine-containing class of oral anti-diabetics, the glimins.
Poxel was established in 2009, when German Merck KGaA merged with Swiss Serono. The company’s platform are those drug candidates for metabolic diseases that Merck-Serono elected not to continue. In 2010 Poxel raised €16m. Now, with refilled pockets, the small company is about to bring Imeglimin through Phase II trials as a monotherapy and as an add-on therapy to the main anti-diabetic agents, starting with metformin and sitagliptin. However, a crucial Phase IIb study starts in early 2013, when Imeglimin's efficacy profile as a monotherapy treatment will be evaluated in a large six-month trial involving 400 diabetic patients.
Imeglimin has a mitochondria-based mechanism of action, targeting the respiratory chain. It acts on the three key defects of Type 2 diabetes, inhibiting hepatic gluconeogenesis, increasing muscle glucose uptake and restoring normal insulin secretion. Thierry Hercend, MD, PhD and Chairman of the board believes that Imeglimin has the „potential to become a new anti-diabetic standard treatment.”
03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more